linjc16/ctgov huggingface dataset:
LOC387715/HTRA1 and the Combined Photodynamic Therapy With Intravitreal Bevacizumab in Polypoidal Choroidal Vasculopathy

Study Overview
=================
Brief Summary
-----------------
This study is to investigate whether there is an association of the LOC387715/HTRA1 variants with response to treatment with combined photodynamic therapy and intravitreal bevacizumab for patients with polypoidal choroidal vasculopathy.

Detailed Description
-----------------
This is a retrospective cohort study comprised of 70 eyes being treated for polypoidal choroidal vasculopathy with combined photodynamic therapy and intravitreal bevacizumab injections. Patients were genotyped for the LOC387715 (rs10490924) and the HTRA1 gene polymorphism (rs11200638).

Official Title
-----------------
LOC387715/HTRA1 Variants and the Response to Combined Photodynamic Therapy With Intravitreal Bevacizumab in Polypoidal Choroidal Vasculopathy

Conditions
-----------------
Age-Related Macular Degeneration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients older than 60 years of age at onset polyp-like terminal aneurysmal dilations with or without branching vascular networks in indocyanine green angiography (ICGA) and subretinal reddish-orange protrusions corresponding to polyp-like lesions patients who had combined photodynamic therapy and intravitreal bevacizumab injections, and followed up for more than 12 months after the first treatment Exclusion Criteria: patients with retinal or choroidal diseases including pathologic myopia, angioid streaks, idiopathic choroidal neovascularization (CNV), presumed ocular histoplasmosis, and other secondary CNV patients who refused genotypic analyses

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| polypoidal choroidal vasculopathy<br>patients who were treated for polypoidal choroidal vasculopathy with combined photodynamic therapy and intravitreal bevacizumab injections | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best-corrected visual acuity | Best-corrected visual acuity (BCVA) using the Snellen chart was evaluated including BCVA up to 12 months | up to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Angiographic characteristics | Fluorescein angiography (FA) and ICGA (HRA; Heidelberg Engineering, Dossenheim, Germany) was evaluated. Greatest linear dimension (GLD) was determined based on both FA and ICGA. | up to 12 months |
Impact of Non-Commercialism Policy in Seattle Schools

Study Overview
=================
Brief Summary
-----------------
This is a 3-year pilot study funded by National Institute of Health will assess and evaluate obesity-related health outcomes of a real-life policy decision, recently voted on and adopted by the Seattle School Board.

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Behavioral: Water, Cafeteria and Staff Health Promotion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: All students who attend Cleveland and Rainier Beach high schools are eligible. Exclusion: Those who are no longer attending those schools.

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Water, Cafeteria and Staff Health Promotion|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to find out whether AIC246 is safe and efficacious in lowering the chances of the cytomegalovirus becoming active again and causing illness after an HBPC transplant (allogeneic stem cell transplant).

Official Title
-----------------
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of 12 Weeks' Treatment With a New Antiviral HCMV Drug

Conditions
-----------------
HCMV Reactivation or HCMV End-Organ Disease

Intervention / Treatment
-----------------
* Drug: 60 mg AIC246
* Drug: 120 mg AIC246
* Drug: 240 mg AIC246
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Seropositive for HCMV IgG antibodies before transplantation First allogeneic Human blood precursor cell (HBPC) transplantation performed for 1 of the following diagnoses: leukaemia, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, myelodysplastic and myeloproliferative disorder Evidence of post transplantation engraftment Able to swallow tablets. Exclusion Criteria: Previous anti-HCMV therapy after this allogeneic HBPC transplantation Mismatched or cord blood transplant recipients Current or history of end-organ HCMV disease Graft versus host disease (GVHD) Impaired liver function Reduced renal function

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dose regimen 1<br>60 mg AIC246, one tablet per day | Drug: 60 mg AIC246<br>* Oral administration<br>|
| Experimental: Dose regimen 2<br>120 mg AIC246, one tablet per day | Drug: 120 mg AIC246<br>* Oral administration<br>|
| Experimental: Dose regimen 3<br>240 mg AIC246, one tablet per day | Drug: 240 mg AIC246<br>* Oral administration<br>|
| Other: Placebo<br>Placebo arm | Other: Placebo<br>* Oral administration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With HCMV Prophylaxis Failure |  | 84 days | 
| Time to Onset of HCMV Prophylaxis Failure |  | 84 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients With Systemic Detectable HCMV Replication. |  | 84 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HCMV
Exclusive Enteral Nutrition for Remissionof Crohn's Diseases After Surgery

Study Overview
=================
Brief Summary
-----------------
For patients with Crohn's diseases undergoing surgery，whether postoperative exclusive enteral nutrition(EEN) could delay the endoscopic relapse needs exploration.The trial will investigate the efficacy of postoperative EEN for maintaining disease remission.

Official Title
-----------------
Exclusive Enteral Nutrition for Remissionof Crohn's Diseases After Surgery

Conditions
-----------------
Crohn Disease in Remission

Intervention / Treatment
-----------------
* Other: 3 months exclusive enteral nutrition after surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - CD patients who undergoing bowel resection with anastomosis Exclusion Criteria: patients who received stoma creation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 3 months exclusive enteral nutrition after surgery<br>3 months exclusive enteral nutrition after surgery | Other: 3 months exclusive enteral nutrition after surgery<br>* patients underwent intestinal resection and anastomosis in this arm will given over 3 months exclusive enteral nutrition,and free diet after 3 months.<br>|
| Experimental: less than 1 months exclusive enteral nutrition after surgery<br>less than 1 months exclusive enteral nutrition after surgery | Other: 3 months exclusive enteral nutrition after surgery<br>* patients underwent intestinal resection and anastomosis in this arm will given over 3 months exclusive enteral nutrition,and free diet after 3 months.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative endoscopic recurrence | over i2b of rutgeerts score | 1 YEAR |
Visual Outcome After Transsphenoidal Surgery for Pituitary Macroadenoma

Study Overview
=================
Brief Summary
-----------------
Endoscopic endonasal transsphenoidal surgery is a procedure for the treatment of pituitary macroadenomas that cause visual impairment through optic chiasm compression. The aim of this retrospective study is to describe visual outcome after this procedure.

Official Title
-----------------
Visual Outcome After Transsphenoidal Surgery for Pituitary Macroadenoma

Conditions
-----------------
Pituitary Tumor, Optic Chiasm Disorder

Intervention / Treatment
-----------------
* Procedure: Endonasal transsphenoidal pituitary tumor removal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pituitary tumor causing optic chiasm compression (documented on MRI or CT-scan) Visual impairment caused by chiasm compression Treatment by transsphenoidal endonasal surgery Treatment in the Rothschild Foundation (Paris) between 2009 and 2013 Exclusion Criteria: Ophtalmologic condition other than optic chiasm compression

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Endonasal transsphenoidal pituitary tumor removal|Removal of pituitary tumor by transsphenoidal endonasal surgery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-operative gain in visual acuity | Difference between pre-operative and post-operative visual acuity, expressed in LogMAR | six months |
Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects

Study Overview
=================
Brief Summary
-----------------
This study is a description of the radiation effects on the healthy tissues in patients receiving Anastrozole, sequential or in association with radiotherapy.

Official Title
-----------------
Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Post-menopausal woman without superior age limit No metastatic breast cancer, stade I-II, estrogen receptor positive or progesterone receptor positive, treated by conservative surgery or total mastectomy and requiring additive treatment by radiotherapy and hormonotherapy The patients including in another clinical trial can be include in this observatory
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Concomitant<br>In this group, anastrazole is concomitant to the radiotherapy | |
| Sequential<br>In this group, anastrazole is sequential to the radiotherapy (start after the end of radiotherapy) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| radiation side effects | Describe, in real situation, the ionisant radiation effects on the healthy tissues in patients receiving anastrazole in association or sequential with radiotherapy | 5 years after the end of radiotherapy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast cancer, radiotherapy, hormonotherapy
Observational Study of Ultravist in Patients Requiring CECT

Study Overview
=================
Brief Summary
-----------------
It is a prospective, non-interventional, multi-center study. The primary objective of this study is to evaluate the image quality of Ultravist in patients requiring contrast-enhanced CT considering the routine use in patient population's, region's indication.

Official Title
-----------------
The Image Quality and Radiation Dose of CECT With Ultravist® in Patients With Abdominal Pelvic Disease - INDEX

Conditions
-----------------
Diagnostic Imaging

Intervention / Treatment
-----------------
* Drug: Iopromide (Ultravist, BAY86-4877)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing contrast enhanced CT Imaging with Ultravist (iopromide) in abdomen or pelvis. Exclusion Criteria: There is no other exclusion criteria beyond the contraindications contained in the Summary of Product Characteristics
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Iopromide (Ultravist, BAY86-4877)<br>* CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Image quality evaluated by calculated CNR (Contrast to Noise Ratio) |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Image quality evaluated by calculated SNR (Signal Noise Ratio) |  | 1 day | 
| Descriptive analysis of contrast medial injection protocol |  | 1 day | 
| Radiation dose (CTDIvol) |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Image quality, CNR, SNR, Abdominal, Pelvic
Canadian CP Registry - Registre Canadien de la Paralysie Cérébrale

Study Overview
=================
Brief Summary
-----------------
The Canadian Cerebral Palsy (CP) Registry is a confidential, nation-wide collection of medical and social information about children with cerebral palsy. The Registry was first implemented in 2003 in 6 administrative regions of Quebec and was later extended to paediatric centres in Newfoundland, Nova Scotia, Ontario, Alberta, and British Columbia. Over 1850 children living with Cerebral Palsy have been registered so far. The Registry is the first national registry for cerebral palsy in North America.

Detailed Description
-----------------
The Canadian Cerebral Palsy Registry is a multi-regional Canadian registry to identify potential risk factors related to pregnancy and interactions of the environment and genetics. The Registry provides researchers with the approximate number of children with cerebral palsy across Canada, and data in the Registry helps researchers explore reasons behind the causes of cerebral palsy, in addition to supporting studies which may lead to improvements in the overall care of children with CP. Cerebral palsy is the most common cause of physical disability in children in Canada and it is important that we gain a better understanding of its prevalence, risk factors and current clinical profile. The Canadian CP Registry provides valuable data from different Canadian regions which can be shared and analyzed so as to provide answers to these important questions. Specifically, the Registry serves to: Characterize the profile of children living with CP across the country Identify risk factors associated with CP Monitor the prevalence of CP across the country Provide a platform for subject recruitment for population-based research on CP

Official Title
-----------------
The Canadian Cerebral Palsy Registry - Le Registre Canadien de la Paralysie Cérébrale

Conditions
-----------------
Cerebral Palsy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Under 18 (age cut-off varies by region) Diagnosed with Cerebral Palsy Living in Canada Exclusion Criteria: Uncertain CP diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterize the CP profile across Canada | CP subtype, severity, and associated conditions | An average of every two years, up to study completion or ten years, whichever comes first. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cerebral Palsy, Canada, Registry
High Intensity and Moderate Training and Maximal Oxygen Uptake and Activity Levels

Study Overview
=================
Brief Summary
-----------------
Aim of the study is to investigate the effect of different types of training (high intensity and moderate training) on maximal oxygen uptake and activity levels in an elderly Norwegian population after one year training intervention. Baseline data include the activity levels assessed through self reported means as well as objectively measured activity data using activity monitors.

Official Title
-----------------
Effect of High Intensity and Moderate Training on Maximal Oxygen Uptake and Activity Levels in an Elderly Norwegian Population

Conditions
-----------------
Ageing

Intervention / Treatment
-----------------
* Behavioral: High Intensity Training
* Behavioral: Moderate Intensity Training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ability to walk at least 1km, born in 1938,1939,1940,1941 or 1942 Sufficiently good health to be able to take part in the study, as determined by the researchers Exclusion Criteria: Illness or disability that precludes exercise or hinders completion of the study Uncontrolled hypertension Symptomatic valve disease, hyper tropic cardio-myopathy or unstable angina Active cancer Test results indicating that study participation is unsafe Inclusion in other studies conflicting with participation in this one

Ages Eligible for Study
-----------------
Minimum Age: 70 Years
Maximum Age: 77 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: High Intensity Training<br>training at high intensities ranging from 85-95% of maximal heart rate | Behavioral: High Intensity Training<br> <br> |
| Experimental: Moderate Intensity Training<br>training at intensities of 65-75% of maximal heart rate | Behavioral: Moderate Intensity Training<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| maximal oxygen uptake |  | 1 year | 
| activity level |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
maximal oxygen uptake, activity levels, elderly
Researches About Proximal Humerus Fractures

Study Overview
=================
Brief Summary
-----------------
Majority of previous classifications based on two-dimensional images to analyze these complicated 3-D fractures. Small or delicate changes in rotation and positioning can result to considerable disagreement in the interpretation of standard radiographs. Therefore, a classification system which had a better reliability and reproducibility for the fractures is warranted and helpful for orthopedic surgeons. Furthermore, CT and 3-D CT construction images with high resolution give a much clearer view of the pattern of proximal humeral fractures. Edelson proposed a new three-dimensional classification for fractures of the proximal humerus. The results concluded that it was a useful in classifying these injuries with reasonable interobserver reliability. It could be hypothesized that patients with proximal humeral fractures would benefit from this 3D classification, but there is a scarcity of application of the classification in large samples. T

Official Title
-----------------
The Reliability and Reproducibility of Edelson Classification About Proxima Humeral Fractures

Conditions
-----------------
Proximal Humeral Fracture

Intervention / Treatment
-----------------
* Other: without intervention, just retrospectively review the data about patients


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Whole imaging data ; Clear record of demographic data; Three dimensional construction with mimics (with CT of B30); Patients older than 17 years with displaced PHF occurring less than 3 weeks before allocation and treatment. Exclusion Criteria: Patients with the presence of neurological disease (syringomyelia and); Open fractures; Pathological fracture (other than osteoporotic); Not a resident in the hospital catchment area

Ages Eligible for Study
-----------------
Minimum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients wiht CT data<br>all patients with CT data are enrolled with this research, and the classification about proximal humeral fractures are identified. | Other: without intervention, just retrospectively review the data about patients<br>* without intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| classification based on Edelson classifications |  | 2019.01-2022.12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Proximal Humeral, Fracture, Classifications